Abstract 1129P
Background
Tebentafusp (tebe) is a bispecific consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100+ cells. Tebe significantly improved overall survival (OS) compared to investigator’s choice of pembrolizumab, ipilimumab or dacarbazine (HR 0.51) in first line (1L) mUM [NCT03070392]. Here we evaluated the impact of subsequent therapy on long-term survival.
Methods
Analyses were conducted on HLA-A*02:01+ patients with first line mUM recruited to the randomized phase III study (Study 202, N=378). Crossover to tebe was not permitted until the planned interim analysis demonstrated significant OS benefit. Inverse probability of censoring weighting (IPCW) was used to compare the tebentafusp and investigator’s choice (IC) arms by removing the effects of subsequent therapies (any versus CPI only). OS from the start of subsequent therapy was compared between arms using Cox regression models adjusted for prognostic baseline covariates.
Results
After a median follow-up of 37.8 months, a similar percentage of patients, ∼ 62%, received subsequent therapy in each arm. Median time to first subsequent therapy was longer for tebe pts (6.4 mo) vs. IC pts (4.5 mo). The most frequent subsequent therapy was CPI in both arms (received by 49% of tebe pts and 34% of IC pts); 17% of IC pts received subsequent tebe. When adjusting for the effect of subsequent therapy (any or CPI), the OS benefit from the ITT analysis was maintained. In an analysis of survival from the start of any first subsequent therapy, prior tebe patients tended to have longer OS compared to prior IC patients, HR (95% CI) 0.75 (0.55, 1.04). This difference was also seen when restricting to patients who received subsequent CPI therapy, HR (95% CI) 0.72 (0.48, 1.09).
Conclusions
Based on IPCW analysis, the OS benefit in first line HLA-A*02:01+ mUM patients is predominantly due to tebentafusp and not due to subsequent therapy. This reinforces the use of tebentafusp in the first line setting. Updated data with a minimum 3 years of follow-up will be presented. 1. Yang J. et al. ASCO 2019 , J. Clin Oncol 37:15_suppl, 9592.
Clinical trial identification
NCT03070392.
Editorial acknowledgement
Legal entity responsible for the study
Immunocore Ltd.
Funding
Immunocore Ltd.
Disclosure
M. Orloff: Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb; Financial Interests, Personal, Speaker, Consultant, Advisor: IDEAYA Biosciences, Immunocore, TriSalus Life Sciences, Delcath Systems; Financial Interests, Institutional, Research Funding: Bristol Myers Squibb, Immunocore, Delcath Systems, Plexxikon, IDEAYA Biosciences, Linnaeus Therapeutics. C. Watkins: Financial Interests, Personal, Speaker, Consultant, Advisor: Celgene/Bristol Myers Squibb, Roche, Immunocore, Ascelia, Humanigen, Astellas Pharma, F2G, Amylyx, Kite/Gilead, Novo Nordick, Neurovalens, Medical Developments International, Servier, EQRx. R.D. Carvajal: Financial Interests, Personal, Speaker, Consultant, Advisor: Alkermes, Bristol Myers Squibb, Castle Biosciences, Delcath, Eisai, Hengrui, IDEAYA, Immunocore, InxMed, Iovance, Merck, Novartis, OncoSec, Pierre Fabre, PureTech Health; Financial Interests, Institutional, Speaker, Consultant, Advisor: Regeneron, Sanofi Genzyme, Trisalus Clinical; Financial Interests, Institutional, Advisory Board: Aura Biosciences, Chimeron, Rgenix. A.N. Shoushtari: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Immunocore, Novartis; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Invited Speaker: Bristol Myers Squibb, Immunocore, Polaris, Xcovery, Pfizer, Novartis, Targovax ASA, Checkmate Pharmaceuticals, Linnaeus Therapeutics, Prelude Therapeutics; Financial Interests, Personal, Invited Speaker: Foghorn Therapeutics; Non-Financial Interests, Member: ASCO. J.J. Sacco: Financial Interests, Personal, Speaker, Consultant, Advisor: Immunocore, Bristol Myers Squibb, MSD, Delcath, Amgen; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, MSD, Pierre Fabre; Financial Interests, Institutional, Research Grant: Immunocore, Bristol Myers Squibb, MSD, Amgen, AstraZeneca, Replimune. M. Schlaak: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Novartis, Merck/MSD, Roche, Pierre Fabre, Kyowa Kirin, Immunocore, Sanofi Genzyme; Financial Interests, Personal, Other, Travel expenses: Sun Pharma. J. Gama: Financial Interests, Personal, Full or part-time Employment: Immunocore. M.O. Butler: Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, Bristol Myers Squibb, Novartis, Sanofi, Pfizer, Adaptimmune, GSK, Immunocore, EMD Serono, Sun Pharma; Financial Interests, Personal and Institutional, Research Grant: Merck; Financial Interests, Personal, Research Grant: Takara Bio; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, Novartis, Sanofi, Adaptimmune, Immunocore, Regeneron, Lilly, Amgen, OncoSeq.
Resources from the same session
1198P - Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
Presenter: Jonathan Strosberg
Session: Poster session 13
1199P - MAVERIC: Phase II randomized study of everolimus as maintenance therapy for metastatic neuroendocrine neoplasms (mNEN) with pulmonary or gastroenteropancreatic (GEP) origin. Results on behalf of the GOIRC
Presenter: Lorenzo Antonuzzo
Session: Poster session 13
1200P - A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial
Presenter: oOttavia Clemente
Session: Poster session 13
1201P - Evaluation of efficacy TEMCAP regiment as first-line or further line therapy in patients with advanced, unresectable, progressive GEP-NET. Real-world data
Presenter: Agnieszka Kolasinska-Cwikla
Session: Poster session 13
1202P - Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)
Presenter: Claudia von Arx
Session: Poster session 13